Background and Purpose-Despite the benefits of tissue-type plasminogen activator treatment, some stroke patients experience adverse hemorrhagic transformations (HT 
T issue-type plasminogen activator (tPA) is the only drug approved for the acute treatment of ischemic stroke, but its great benefits are counterbalanced by undesired effects such as symptomatic hemorrhagic transformations (HT), occurring in 1.5% to 4% of cases. 1 Symptomatic HT are parenchymal hemorrhages associated with high mortality and neurological worsening. To minimize bleedings, a precise selection of ischemic stroke patients is mandatory, leading to only 14% of them being benefited by the use of the drug. 2 Previous studies observed that increased metalloproteinase-9 (MMP9) levels measured in plasma samples of patients before tPA administration were associated with HT occurrence. 3 Our aim was to perform a thorough study of the MMP9 gene to determine if genetic variations might be the reason for HT occurrence and increased plasma MMP9 levels in some tPA-treated patients.
Subjects and Methods

Study Population
Our target group consisted of consecutive white patients (nϭ885) experiencing an acute ischemic stroke who received tPA in a standard 0.9-mg/kg dose within the first 4.5 hours after symptoms onset. The mean age was 70.5Ϯ12.0 years, 54.8% were men, and 22% had development of an HT (9.6% had a parenchymal hemorrhage subtype).
HT presence was excluded before tPA infusion by MRI or CT scan. HT was evaluated in a follow-up CT scan performed 24 hours after symptoms onset or whenever neurological worsening occurred and was classified according to ECASS criteria. 4 Complete clinical and methodological data are available in the online-only Supplemental Methods and in the online-only Supplemental Table I (http://stroke.ahajournals.org).
Genetic and Functional Analysis
We attempted to genotype 14 tag-SNP located in the MMP9 gene in 885 samples using data from the Hapmap project (http://hapmap. ncbi.nlm.nih.gov/). Genotyping was conducted by SNPlex technology. The analysis of haplotypes was performed using the PHASE software. Imputation was performed using our genotyping data and according to the recommendations of the PLINK software (http://pngu.mgh.harvard.edu/ϳpurcell/plink/).
We analyzed the (CA) n microsatellite, previously associated with MMP9 expression in cell cultures, 5 in 885 samples. Primers were labeled with fluorescence, and the polymerase chain reaction amplicons were checked on an ABI 3730 DNA analyzer (Applied Biosystems).
We screened the promoter region of the MMP9 gene by direct sequencing (2 Kb upstream of the transcription start site) in a subset of 10 HT patients and 10 non-HT patients matched for age and gender to find rare mutations. All the variations detected were compared with data integrated from the dbSNP database (37.1 built) to determine whether they were new mutations or previously described SNP.
Fifty-four subjects, including 41% with HT (20.9% with a parenchymal hemorrhage subtype), were included in the analysis of the association of genotyped SNP, imputed SNP, haplotypes, (CA) n microsatellite, and HT occurrence with MMP9 gene expression. RNA was extracted from blood samples at baseline (before tPA administration) and 1 hour after tPA. The mRNA levels were measured by real-time polymerase chain reaction using TaqMan fluorogenic probes and a 7500 Real-Time PCR System (Applied Biosystems).
Statistical Analysis
Sample size calculation was performed using the Ene 2.0 software. The 14 SNP with frequencies higher than 0.35 in the experimental group (HT subjects) and lower than 0.20 in the reference group (non-HT subjects) would be found significantly associated with a power of 80% in a sample of 138 subjects, for unadjusted Pϭ0.05. In addition, the analysis of the 14 SNP together and an adjusted Pϭ0.05 (using Bonferroni correction) showed robust statistical power (online-only Supplemental Figure I ).
The Hardy-Weinberg equilibrium was assessed using a 2 
Results
Fourteen SNP were successfully genotyped in 836 DNA samples; all of them were in Hardy-Weinberg equilibrium. Additive and dominant/recessive models were used. We did not find any SNP significantly associated with HT occurrence (online-only Supplemental Table II and Table III) . After the imputation process and quality control tests, we analyzed 6 new SNP. We did not find any imputed SNP associated with HT occurrence (online-only Supplemental Table IV) .
Using the PHASE software, we obtained 13 different haplotypes (online-only Supplemental Table V ). The H1 haplotype was the most frequent (54.9%), followed by the H2 (22%). No significant association between the haplotypes and HT occurrence was observed. None of the (CA) n repetitions detected was associated with HT occurrence.
Last, we did not find any new mutation in HT (parenchymal hemorrhage subtype) or non-HT subjects when we screened the promoter region of the gene.
No significant difference in the mean relative levels of RNA expression was observed between subjects depending on the genotyped SNP, imputed SNP, haplotypes, or (CA) n microsatellite. Moreover, MMP9 mRNA levels were not associated with HT occurrence (Figure) .
Discussion
In our study, we found that the MMP9 gene variants are not related to HT occurrence after tPA administration. We aimed to perform the first complete study of the MMP9 gene because plasma levels of the protein play an important role in HT occurrence, and we hypothesized that genetic factors of MMP9 could be associated with HT occurrence in some patients. However, after an extended analysis of the MMP9 gene, we did not find any genetic marker associated with the HT process.
The well-powered analysis by tag-SNP, imputed SNP, and haplotypes did not reveal any association between any polymorphism and HT. When we studied the presence of rare mutations, we did not find any new mutation that could modify the transcription process and increase the levels of the protein.
Moreover, when we analyzed the expression levels of the gene, we did not find any association with HT occurrence or with the SNP or haplotypes analyzed. Nevertheless, it should be noticed that we analyzed MMP9 expression in blood and the MMP9 expression could be different in other tissues, such as brain.
Several studies have revealed a genetic predisposition in tPA safety and efficacy. The Val34Leu SNP of the FXIII gene was associated with HT rates after tPA treatment. 6 Previously, we analyzed the role of a common polymorphism (C-1562T) in the MMP9 gene. 7 This SNP was associated with MMP9 levels in vitro; however, we did not observe any association with HT rates. 7 Altogether, our results suggest that the MMP9 gene is not associated with HT. The increase in MMP9 levels observed in HT patients might be caused by a different process in which the MMP9 gene is not involved. The ␣-2-macroglobulin, low-density-related protein-1, and tissue inhibitors of metalloproteinases are molecules that inhibit MMP9 and modulate its plasma levels. 8 Moreover, we have observed that neutrophils releasing MMP9 are involved in the HT process, 9 and a great interindividual load difference of MMP9 exists in the vesicles of human neutrophils that are degranulated after contacting with tPA. 10 We conclude that the MMP9 gene is not associated with HT occurrence and another process might be involved in HT after tPA administration. Our data suggest that preformed MMP9 (ie, filling neutrophil vesicles) instead of newly synthesized protein might be more relevant in the HT process.
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Study Population
Our target group consisted of consecutive Caucasian patients suffering from an acute ischemic stroke admitted to the emergency room and who received t-PA in a standard 0.9-mg/kg dose (10% bolus, 90% continuous infusion during 1 hour), within the first 4.5 hours of symptoms onset.
The study cohort (n=885) was recruited in five different Spanish university hospitals between November 2000 and June 2008. The mean age was 70.5±12.0 years, 54.8% were men, 59.1% of the patients were hypertensive, 35.5% presented atrial fibrillation, 21.0% had a history of diabetes mellitus and 22.1% developed a HT (9.6% a PH subtype) (see complete data in Supplemental Table 1 ).
We genotyped the entire promoter region in a subset of 10 TH patients and 10 non-TH patients matched for age and gender in order to find new pathological mutations of low frequency and we analyzed MMP9 RNA in a subset of 54 samples (22 with HT) from which RNA was available.
Clinical protocol
A detailed history of vascular risk factors was obtained from each patient. Clinical examination was performed on admission and at later time points (1 and 2 hours after t-PA administration and 24 and 48 hours after symptoms onset). Stroke severity and neurological worsening were assessed with the National Institutes of Health Stroke Scale (NIHSS) (5). The Modified Rankin Scale (mRS) was used 3 months after the event to evaluate functional outcome (patients with mRS score>2 were considered dependent). On admission and within the first 4.5 hours of stroke symptoms onset, all patients underwent a CT scan which was repeated after 24 hours (or earlier when a rapid neurological deterioration occurred), to check for the presence of HT. The CT scans were reviewed by a neuroradiologist with extensive experience in acute stroke, who was blinded to clinical details. Presence and type of HT were defined according to previously published criteria (6) . Hemorrhagic infarction (HI) was defined as a petechial infarction without space-occupying effect, and parenchymal hematoma (PH) was defined as hemorrhage with mass effect. HI-1, small petechiae along the margins of the infarct; HI-2, more confluent petechiae within the infarcted area; PH-1, when hematoma involved ≤ 30% of the infarcted area with slight space-occupying effect; PH-2, when hematoma involved > 30% of the infarcted area with substantial mass effect, or clot remote to the infarcted area.
The Ethics Committee of the Hospital approved the study and all patients or relatives gave informed consent.
Genetic analysis
We aimed to genotype 14 tag SNPs located in the MMP9 gene using data from the Hapmap project (http://hapmap.ncbi.nlm.nih.gov/), tagger pairwise, MAF>0.1 (minor Allele Frequency), r 2 >0.8 and Centre European population settings. Genotyping was carried out at the Spanish National Genotyping Centre (Barcelona, Spain), using SNPlex™ technology and a 3730/3730xl DNA analyzer (Applied Biosystems, Foster City, California). The samples were assigned in 90 wells plates with 48 SNPs batches using GeneMapper 3.5 as allele calling algorithm, with a mean call rate of 90%. As quality control, two HapMap samples (NA10860 and NA10861) were included, whose genotype concordance was verified using SNPator (www.snpator.org, CeGen) (7). Moreover, SNPlex genotyping accuracy was validated in our series by PCR and direct sequencing. Finally, the 14 SNPs reached the minimal call rate and Minor Allele Frequency criteria (MAF>0.1%).
Haplotypes analyses were performed using the PHASE software implemented in SNPator (www.snpator.org, CeGen) (7). Imputation was carry out following the recommendations of the PLINK software (http://pngu.mgh.harvard.edu/~purcell/plink/). Briefly, we used our own data to impute non-monomorphic, autosomal SNPs described in HapMap's European population panel in the MMP9 gene region. Quality control analyses were performed to select the imputed SNPs with an INFO value (Information content metric) greater than 0.8. We analyzed the (CA)n microsatellite that was previously described as associated with MMP9 RNA expression in cell cultures (8) . Forward primers were labelled fluorescently, and the resulting fluorescent PCR amplicons were then checked on an ABI 3730 DNA analyzer (Applied Biosystems, Foster City, CA, USA). Electropherograms were studied with the Fragment Analysis and Peak Scanner v1.0 softwares. PCR conditions and primers sequences are available upon request. We screened the promoter region of the gene by PCR and direct sequencing (2 Kb before transcription origin) in a subset of 10 HT patients and 10 non-HT patients matched for age and gender. The resulting electropherograms were studied and all variations detected were compared with the data of the dbSNP database to determine whether it was a new mutation or a previously described SNP. PCR conditions and primers sequences are available upon request.
Functional studies
Fifty-four subjects, 41% with a HT (20.9% with a PH subtype) were used to check the association of genotyped SNPs, imputed SNPs, haplotypes and (CA)n microsatellite with MMP9 gene expression. RNA was extracted from blood samples of 54 patients obtained at baseline (before t-PA administration) and 1 hour after tPA infusion. EDTA tubes were centrifuged at 3500 rpm for 15 min to obtain the white blood cell fraction. RiboPure TM -Blood kits (Ambion, Woodward st. Austin, USA) were used to extract total RNA following the manufacturer's instructions. mRNA levels were measured by real-time PCR, using TaqMan fluorogenic probes and a 7500 Real Time PCR System (Applied Biosystems, Foster city, CA, USA). Cyclophilin A (PPIA) expression (Hs0099999904_m1) was used to normalize the results. Real-time PCR was performed using a standard TaqMan ® PCR kit protocol consisting of 20 µl PCR mix including 5 µl cDNA, 10 µl 2x TaqMan ® Universal PCR Master Mix (P/N: 4304437, Applied Biosystems, Foster city, CA, USA), 1µl of Taqman gene expression assay and 4 µl of water. Reactions were performed in a 96-well plate at 50ºC for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. A ll reactions were run in triplicates and analyzed using the Applied Biosystems SDS 7500 system software (Applied Biosystems, Foster city, CA, USA). The results are expressed in % depending on a healthy calibrator sample used in the experiments.
Statistical analysis
Sample size calculation was performed using the Ene 2.0 software. The 14 SNPs with frequencies higher than 0.35 in the experimental group (HT subjects) and lower than 0.20 in the reference group (no-HT subjects) would be found significantly associated with a power of 80% in a sample size of 138 subjects in each branch.
The Hardy-Weinberg equilibrium was assessed using a χ 2 test with 1 degree of freedom. SPSS statistical package version 15.0 was used for data analysis. Statistical significance for intergroup differences was assessed by the χ 2 or Fisher's exact test for categorical variables. The Anova or Kruskal-Wallis tests were used when two groups were analyzed; T-Test or MannWhitney U tests were used when three or more groups were analyzed. False Discovery Rate (FDR) and Bonferroni's test were used to correct for multiple testing. A pvalue <0.05 was considered statistically significant. Table and Figure legends.   Table 1 . Clinical and demographic data. Table 2 . Additive model analysis. P-values are unadjusted. Table 3 . Dominant/Recessive model analysis. P-values are unadjusted. Table 4 . Association of imputed SNPs with HT occurrence. P-values are unadjusted. Table 5 . Association between haplotypes and HT occurrence. P-values are unadjusted. SNPs of the haplotypes: rs8113877, rs3918278, rs3918241, rs3918243, rs3918280, rs3918248, rs3918249, rs3918253, rs2274755, rs2236416, rs3918256, rs3787268, rs2250889, rs2274756 Figure 1 . The graphs represent the statistical power depending on the sample size used (the total sample size of our study was 885). Results considering an adjusted p-value of 0.05 (using Bonferroni correction). X-axis: sample size (total number of samples), Y-axis: statistical power. 
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